Any current/future new fundraising through debt or equity?

Alembic Pharmaceuticals Limited did not mention any current or future new fundraising through debt or equity during the call. The company highlighted that their gross borrowings have reduced from Rs. 686 crores in December 2022 to Rs. 575 crores in December 2023. They reported having Rs. 156 crores of cash on hand as of December 2023. No large CAPEX is planned for the international business other than maintenance CAPEX and some API expansions. The company repaid borrowings and paid dividends from net cash inflows. Overall, the company appears focused on optimizing existing resources and rampin

Any current/future capex/capital investment/strategic investment?

No large CAPEX needed for the international business currently; only maintenance CAPEX and some API expansion planned. API expansion includes growth in therapies such as GLP-1 and debottlenecking. Focus on investments in new capabilities like injectables, peptides, and oncology. The shift toward more complex products aims to reduce price erosion and provide bigger product opportunities, especially in the US market. New facilities are operational but currently have low capacity utilization; operating leverage is expected to improve as product volumes increase. Some targeted CMO (Contr

Future growth expectations in sales/revenue/volumes?

US business: - Expected to grow with broader product portfolio and new product launches (10-15 launches planned in FY25). - Volume increase observed in existing products; new facilities ramp-up to improve operating leverage and margins. - Price erosion continues but is less severe than before; depends on product and competition. - Focus on complex products like injectables, peptides, oncology, which may reduce price erosion and offer larger opportunities. Ex-US markets (Europe, Canada, Australia, Brazil, South Africa): - Steady growth expected at ~15% CAGR, driven through partners.

Future growth expectations in earnings/operating earnings/profits/EPS?

Alembic Pharmaceuticals expects continued growth driven by new product launches, especially in the US generics market with 10-15 launches planned in FY25. The US business is currently profitable and anticipated to improve as operating leverage rises with increased capacity utilization. Operating leverage will improve as new manufacturing facilities ramp up, helping reduce costs and enhance margins. R&D expenses are being optimized, focusing on complex products like injectables, peptides, oncology, and ophthalmics, which should result in better pricing and less erosion. EPS for Q3FY24 before no

IN US

Sale is live|00:00:00left today

Alembic Pharmaceuticals LtdQ4 FY25Pharmaceuticals & Biotechnology

Alembic Pharmaceuticals Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹772P/E: 21.1Market Cap: ₹15.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→US business:
→ - Expected to grow with broader product portfolio and new product launches (10-15 launches planned in FY25).
→ - Volume increase observed in existing products; new facilities ramp-up to improve operating leverage and margins.
→ - Price erosion continues but is less severe than before; depends on product and competition.
→ - Focus on complex products like injectables, peptides, oncology, which may reduce price erosion and offer larger opportunities.
→Ex-US markets (Europe, Canada, Australia, Brazil, South Africa):
→ - Steady growth expected at ~15% CAGR, driven through partners.
→API business:
→ - Continues to be a good margin business with steady growth (~11-15% CAGR).
→ - Some near-term lumpiness expected, followed by return to regular growth.
→Domestic India business:
→ - 9% growth reported despite muted demand in some segments.
→ - Specialty therapies and Animal Health showing strong growth.
→Overall:
→ - Incremental operating leverage expected as new facilities grow utilization.
→ - No major CAPEX planned except maintenance and API expansions.

Margin guidance

Category 3

→Alembic Pharmaceuticals expects continued growth driven by new product launches, especially in the US generics market with 10-15 launches planned in FY25.
→The US business is currently profitable and anticipated to improve as operating leverage rises with increased capacity utilization.
→Operating leverage will improve as new manufacturing facilities ramp up, helping reduce costs and enhance margins.
→R&D expenses are being optimized, focusing on complex products like injectables, peptides, oncology, and ophthalmics, which should result in better pricing and less erosion.
→EPS for Q3FY24 before non-recurring items is Rs. 9.18 vs. Rs. 6.76 YoY, indicating strong profit growth.
→EBITDA margins expected to improve with better capacity utilization and cost control; tax rate normalized at around 17-18% for FY25.
→The company anticipates steady revenue growth in ex-US markets (~15% CAGR) and recovery in API business after a temporary slowdown.

3 more insights locked — sign up free to unlock

Fundraise plans

→Alembic Pharmaceuticals Limited did not mention any current or future new fundraising through debt or equity during the call.
→The company highlighted that their gross borrowings have reduced from Rs. 686 crores in December 2022 to Rs. 575 crores in December 2023.
→They reported having Rs. 156 crores of cash on hand as of December 2023.
→No large CAPEX is planned for the international business other than maintenance CAPEX and some API expansions.
→The company repaid borrowings and paid dividends from net cash inflows.
→Overall, the company appears focused on optimizing existing resources and ramping up new facilities without raising additional capital through debt or equity at this time.

Order book

The transcript does not explicitly mention current or expected orderbook or pending orders for Alembic Pharmaceuticals Limited. However, relevant points related to business outlook and operations include: - New facilities are operational but currently have low capacity utilization; operating leverage expected to improve as product launches increase. - 11 product launches in Q3 FY24 and about 5 products expected in Q4 FY24, with 10-15 launches anticipated in FY25. - Ongoing evaluations for long-term contracts in the US generics business, but no contracts finalized yet. - Growth in US business volumes and expansion in ex-US markets like Europe, Canada, Australia, Brazil, and South Africa through partners. - Pursuit of CMO (Contract Manufacturing Organization) opportunities to improve plant utilization. - No large CAPEX planned; focus on maintenance and API expansions. No specific quantitative details on orderbook or pending orders are provided in the transcript.

Capex plans

Yes

→No large CAPEX needed for the international business currently; only maintenance CAPEX and some API expansion planned.
→API expansion includes growth in therapies such as GLP-1 and debottlenecking.
→Focus on investments in new capabilities like injectables, peptides, and oncology.
→The shift toward more complex products aims to reduce price erosion and provide bigger product opportunities, especially in the US market.
→New facilities are operational but currently have low capacity utilization; operating leverage is expected to improve as product volumes increase.
→Some targeted CMO (Contract Manufacturing Organization) opportunities are being pursued to improve plant utilization.
→No specific timelines or large-scale new capital investments mentioned beyond these incremental expansions and optimizations.

How does Alembic Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alembic Pharmaceuticals Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Alembic Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio